Litcius/Paper detail

36MO Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer

Adrian G. Sacher, Xiuning Le, Robin Cornelissen, Elaine Shum, Jennifer M. Suga, Mark A. Socinski, Julian R. Molina, Eric B. Haura, Jeffrey Clarke, Gajanan Bhat, François Lebel, M.C. Garassino

2021Annals of Oncology25 citationsDOI

Topics & Concepts

MedicineTolerabilityRashLung cancerInternal medicineAdverse effectOncologyGastroenterologyLung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchColorectal Cancer Treatments and Studies
36MO Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer | Litcius